key: cord-0683442-x1o7vx7w
authors: Poignon, Corentin; Blaize, Marion; Vezinet, Corinne; Lampros, Alexandre; Monsel, Antoine; Fekkar, Arnaud
title: Invasive pulmonary fusariosis in an immunocompetent critically ill patient with severe COVID-19
date: 2020-06-30
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.06.026
sha: caa64679a5cd9ee8eeeeaf6486f5d51569f0669c
doc_id: 683442
cord_uid: x1o7vx7w

nan

Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may develop severe coronavirus disease (COVID-19) and acute respiratory failure. As the lung parenchyma is seriously damaged, opportunistic infections are dreaded. While invasive pulmonary mold superinfections are usually diagnosed primarily in highly immunocompromised patients, invasive aspergillosis has also been described in immunocompetent patients infected with influenza or SARS-CoV (responsible for the Severe Acute Respiratory Syndrome outbreak in [2002] [2003] . Moreover, we recently reported a case of invasive aspergillosis in an immunocompetent critically ill patient with severe COVID-19 [1] . Another study also suggested an increased risk of Aspergillus superinfection in COVID-19 patients [2] .

To know whether or not COVID-19 is a factor promoting invasive pulmonary mold infections in immunocompetent individuals is of great medical interest. We report here the case of an immunocompetent diabetic patient with severe COVID-19 who developed a pulmonary fusariosis due to the common environmental mold Fusarium proliferatum.

A 57-year-old man was addressed to our hospital after 7 days of fever and cough worsening over the last 24 hours. On admission the patient presented signs of acute respiratory failure and was rapidly transferred to our Intensive Care Unit (ICU) on March 26 (Day 1) where he was intubated and placed under mechanical ventilation ( Figure 1 ). The patient had no history of any acquired or inherited immunodeficiency and no underlying respiratory disease. He was overweight (body mass index = 30.6 kg/m 2 ) with type 2 diabetes (blood glucose = 11.6 mmol/L and glycosuria = 1.4 mmol/L on admission), hypertension, and a substituted hypothyroidism. SARS-CoV-2 viral RNA was detected on admission on a tracheal aspiration.

The patient's condition worsened with a PaO 2 /FIO 2 ratio <90 mm Hg with a FiO 2 of 100%. A protected specimen brush sample performed on day 2 remained sterile. While the patient's condition showed no improvement, a bronchoalveolar lavage (BAL) was performed on day 7.

On day 9 this sample grew with 7x10 2 /mL colony-forming unit (CFU) of mold while no bacteria were detected. The same day, a second BAL was performed: atypical fungal hyphae were detected on microscopic examination, testing for galactomannan antigen was positive (index: 1.7) and the sample grew with 10 3 /mL CFU of mold. The different cultures were identified as Fusarium proliferatum by mass spectrometry (Bruker Microflex with MSI database) and a liposomal amphotericin B-based therapy was started on day 12 (5 mg/kg/day for 2 days then 7 mg/kg/day). Invasive aspergillosis is a well-recognized complication of severe influenza pneumonia and has been reported in patients with SARS-CoV and SARS-CoV-2 infections [1, 2] . As fusariosis share many common characteristics with aspergillosis [6] , occurrence of fusariosis in immunocompetent critically ill patients with severe pulmonary damage is possible. If we draw a parallel between fusariosis and aspergillosis, the case we describe is a putative invasive fusariosis according to the classification defined by Blot et al. for the diagnosis of invasive aspergillosis in critically ill patients [7] . Serum beta-glucan and galactomannan testing in serum were negative. Here again a resemblance can be drawn here again with what is observed during invasive aspergillosis in immunocompetent patients where blood tests are often negative while respiratory samples establish the diagnosis [7] .

In conclusion, we report a case of pulmonary fusariosis in an immunocompetent patient with severe SARS-CoV-2 pneumonia. As the outbreak continues to spread worldwide, other reports are needed to assess the frequency of fungal superinfections during severe COVID-19. None.

The authors declare no competing interest

CP and MB collected mycological data, performed antifungal susceptibility testing and EUCAST checkboard method and participated in the writing, CV participated in the therapeutic decision, collected clinical data and participated in the writing, AL participated in the therapeutic decision and in the writing, AM participated in the therapeutic decision, collected clinical data and participated in the writing, AF participated to therapeutic decision, collected data and wrote the paper.

Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient

Covid-19 associated pulmonary aspergillosis

Improvement in the outcome of invasive fusariosis in the last decade

Resolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: A case report

In vitro synergy of caspofungin and amphotericin b against aspergillus and fusarium spp

A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients